These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37930606)

  • 1. CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
    Li S; Zhao G; Wu W; Li N; Wang Q; Wang W; Song X; Wang X
    Clin Exp Med; 2023 Dec; 23(8):4649-4664. PubMed ID: 37930606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Long F; Lin Z; Long Q; Lu Z; Zhu K; Zhao M; Yang M
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
    Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.
    Wang L; Luo J; Nian Q; Xiao Q; Yang Z; Liu L
    Hematology; 2014 Jun; 19(4):225-31. PubMed ID: 24074450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population.
    Xu F; Han R; Zhang J; Li Z; Wang J; Chu XL; Yu JQ; Wang C; Tao T; Shen HJ; Chen SN; Wu DP; Liu SB; Qiu QC; Xue SL
    Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):e107-e115. PubMed ID: 30555035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.
    Nian Q; Xiao Q; Wang L; Luo J; Chen LP; Yang ZS; Liu L
    Int J Mol Med; 2014 Apr; 33(4):856-62. PubMed ID: 24535175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.
    Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Prognostic Factors in 86 Chinese Patients with Primary Myelodysplastic Syndromes and Trisomy 8: A Single Institution Experience.
    Yue QF; Chen L; She XM; Hu B; Hu Y; Zou P; Liu XY
    Yonsei Med J; 2016 Mar; 57(2):358-64. PubMed ID: 26847287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
    Wang J; Wang T; Li S; Lin L; Gang Y
    Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Jain AG; Ball S; Aguirre L; Al Ali N; Kaldas D; Tinsley-Vance S; Kuykendall A; Chan O; Sweet K; Lancet JE; Padron E; Sallman DA; Komrokji R
    Haematologica; 2024 Jul; 109(7):2157-2164. PubMed ID: 38299605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
    J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
    Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
    Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
    Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
    J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.